164 related articles for article (PubMed ID: 31120355)
21. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
Weigert O; Weidmann E; Mueck R; Bentz M; von Schilling C; Rohrberg R; Jentsch-Ullrich K; Hiddemann W; Dreyling M
Leuk Lymphoma; 2009 May; 50(5):716-22. PubMed ID: 19347767
[TBL] [Abstract][Full Text] [Related]
22. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study
Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Pereira J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F
Leuk Lymphoma; 2019 Jan; 60(1):172-179. PubMed ID: 28583031
[TBL] [Abstract][Full Text] [Related]
23. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
24. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma.
Furtado M; Johnson R; Kruger A; Turner D; Rule S
Br J Haematol; 2015 Jan; 168(1):55-62. PubMed ID: 25146720
[TBL] [Abstract][Full Text] [Related]
25. Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial.
Romancik JT; Chen Z; Allen PB; Waller EK; Valla K; Colbert A; Rosand C; Palmer AF; Flowers CR; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1084-e1091. PubMed ID: 36180329
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
Wang XX; Gao Y; Jin J; Cao JN; Feng JF; Wang HQ; Zhang HL; Cai QQ; Li ZM; Jiang WQ; Huang HQ;
Ann Hematol; 2021 Dec; 100(12):2961-2968. PubMed ID: 34331111
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
28. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
[TBL] [Abstract][Full Text] [Related]
29. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
[TBL] [Abstract][Full Text] [Related]
30. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
[TBL] [Abstract][Full Text] [Related]
31. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
32. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
33. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
Kouroukis CT; Fernandez LA; Crump M; Gascoyne RD; Chua NS; Buckstein R; Turner R; Assouline S; Klasa RJ; Walsh W; Powers J; Eisenhauer E
Leuk Lymphoma; 2011 Mar; 52(3):394-9. PubMed ID: 21323520
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib in the treatment of mantle cell lymphoma.
Robak T
Future Oncol; 2015; 11(20):2807-18. PubMed ID: 26347482
[TBL] [Abstract][Full Text] [Related]
36. Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1.
Jiang Z; Zhang A; Wei W; Li S
Sci Rep; 2023 May; 13(1):8389. PubMed ID: 37225761
[TBL] [Abstract][Full Text] [Related]
37. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
Sonbol MB; Hilal T; Dueck AC; Rosenthal AC; Conley CR; Kosiorek HE; Ginos BF; Gano KM; Nichols CS; Leis JF; Johnston PB; Habermann TM; Northfelt DW; Bergsagel PL; Inwards DJ; Witzig TE; Ansell SM; Reeder CB
Leuk Lymphoma; 2018 Sep; 59(9):2128-2134. PubMed ID: 29320913
[TBL] [Abstract][Full Text] [Related]
38. A phase I study evaluating ibritumomab tiuxetan (ZevalinĀ®) in combination with bortezomib (VelcadeĀ®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.
Beaven AW; Shea TC; Moore DT; Feldman T; Ivanova A; Ferraro M; Ford P; Smith J; Goy A
Leuk Lymphoma; 2012 Feb; 53(2):254-8. PubMed ID: 21812533
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
40. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Leonard JP; LaCasce AS; Smith MR; Noy A; Chirieac LR; Rodig SJ; Yu JQ; Vallabhajosula S; Schoder H; English P; Neuberg DS; Martin P; Millenson MM; Ely SA; Courtney R; Shaik N; Wilner KD; Randolph S; Van den Abbeele AD; Chen-Kiang SY; Yap JT; Shapiro GI
Blood; 2012 May; 119(20):4597-607. PubMed ID: 22383795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]